A 28-Year History of HIV-1 Drug Resistance and Transmission in Washington, DC

Washington, DC consistently has one of the highest annual rates of new HIV-1 diagnoses in the United States over the last 10 years. To guide intervention and prevention strategies to combat DC HIV infection, it is helpful to understand HIV transmission dynamics in a historical context. Toward this aim, we conducted a retrospective study (years 1987–2015) of 3,349 HIV pol sequences (1,026 bp) from 1,995 individuals living in the DC area belonging to three different cohorts. We coupled HIV sequence data with clinical information (sex, risk factor, race/ethnicity, viral load, subtype, anti-retroviral regimen) to identify circulating drug resistant mutations (DRM) and transmission clusters and assess their persistence over time. Of the transmission clusters identified in the DC area, 78.0 and 31.7% involved MSM and heterosexuals, respectively. The longest spread of time for a single cluster was 5 years (2007–2012) using a distance-based network inference approach and 27 years (1987–2014) using a maximum likelihood phylogenetic approach. We found eight subtypes and nine recombinants. Genetic diversity increased steadily over time with a slight peak in 2009 and remained constant thereafter until 2015. Nucleotide diversity also increased over time while relative genetic diversity (BEAST) remained relatively steady over the last 28 years with slight increases since 2000 in subtypes B and C. Sequences from individuals on drug therapy contained the highest total number of DRMs (1,104–1,600) and unique DRMs (63–97) and the highest proportion (>20%) of resistant individuals. Heterosexuals (43.94%), MSM (40.13%), and unknown (44.26%) risk factors showed similar prevalence of DRMs, while injection drug users had a lower prevalence (33.33%). Finally, there was a 60% spike in the number of codons with DRMs between 2007 and 2010. Past patterns of HIV transmission and DRM accumulation over time described here will help to predict future efficacy of ART drugs based on DRMs persisting over time and identify risk groups of interest for prevention and intervention efforts within the DC population. Our results show how longitudinal data can help to understand the temporal dynamics of HIV-1 at the local level.

[1]  Sergei L. Kosakovsky Pond,et al.  Combining Phylogenetic and Network Approaches to Identify HIV-1 Transmission Links in San Mateo County, California , 2018, Front. Microbiol..

[2]  D. Molenaar,et al.  Naturally Fermented Milk From Northern Senegal: Bacterial Community Composition and Probiotic Enrichment With Lactobacillus rhamnosus , 2018, Front. Microbiol..

[3]  D. Shortino,et al.  Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States , 2018, AIDS research and human retroviruses.

[4]  R. Dewar,et al.  Early Presence of HIV-1 Subtype C in Washington, D.C. , 2018, AIDS research and human retroviruses.

[5]  Steven Weaver,et al.  HIV-TRACE (TRAnsmission Cluster Engine): a Tool for Large Scale Molecular Epidemiology of HIV-1 and Other Rapidly Evolving Pathogens. , 2018, Molecular biology and evolution.

[6]  Juan C. Sánchez-DelBarrio,et al.  DnaSP 6: DNA Sequence Polymorphism Analysis of Large Data Sets. , 2017, Molecular biology and evolution.

[7]  Taylor J. Maxwell,et al.  Characterization of HIV diversity, phylodynamics and drug resistance in Washington, DC , 2017, PloS one.

[8]  B. van Swinderen,et al.  Response to: Comment on Rohrscheib et al. 2016 "Intensity of mutualism breakdown is determined by temperature not amplification of Wolbachia genes" , 2017, PLoS pathogens.

[9]  William T. Robinson,et al.  HIV Among MSM and Heterosexual Women in the United States: An Ecologic Analysis , 2017, Journal of acquired immune deficiency syndromes.

[10]  Ben Murrell,et al.  Social and Genetic Networks of HIV-1 Transmission in New York City , 2017, PLoS pathogens.

[11]  N. Benbow,et al.  HIV-1 Infection and Transmission Networks of Younger People in Chicago, Illinois, 2005-2011 , 2017, Public health reports.

[12]  D. Katzenstein,et al.  Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  J. Albert,et al.  HIV-1 transmission between MSM and heterosexuals, and increasing proportions of circulating recombinant forms in the Nordic Countries , 2016, Virus evolution.

[14]  J. Mandrekar,et al.  HIV-1 subtype diversity among clinical specimens submitted for routine antiviral drug resistance testing in the United States. , 2015, Diagnostic microbiology and infectious disease.

[15]  Sarah A. Butcher,et al.  Hydrophobin Film Structure for HFBI and HFBII and Mechanism for Accelerated Film Formation , 2014, PLoS Comput. Biol..

[16]  Michele Santacatterina,et al.  Temporal Trends in the Swedish HIV-1 Epidemic: Increase in Non-B Subtypes and Recombinant Forms over Three Decades , 2014, PloS one.

[17]  Dong Xie,et al.  BEAST 2: A Software Platform for Bayesian Evolutionary Analysis , 2014, PLoS Comput. Biol..

[18]  D. Dunn The increasing genetic diversity of HIV-1 in the UK, 2002–2010 , 2014, AIDS.

[19]  Alexandros Stamatakis,et al.  RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies , 2014, Bioinform..

[20]  J. Delfraissy,et al.  Past, present and future: 30 years of HIV research , 2013, Nature Reviews Microbiology.

[21]  Anne-Mieke Vandamme,et al.  Automated subtyping of HIV-1 genetic sequences for clinical and surveillance , 2013 .

[22]  R. Stephens,et al.  HIV Populations Are Large and Accumulate High Genetic Diversity in a Nonlinear Fashion , 2013, Journal of Virology.

[23]  W. Switzer,et al.  Detailed Molecular Epidemiologic Characterization of HIV-1 Infection in Bulgaria Reveals Broad Diversity and Evolving Phylodynamics , 2013, PloS one.

[24]  A. Lansky,et al.  Piloting a System for Behavioral Surveillance Among Heterosexuals at Increased Risk of HIV in the United States , 2012, The open AIDS journal.

[25]  R. Mayeux,et al.  Epidemiology of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[26]  S. Vermund,et al.  The HIV Epidemic: High-Income Countries. , 2012, Cold Spring Harbor perspectives in medicine.

[27]  D. Hazuda,et al.  HIV-1 antiretroviral drug therapy. , 2012, Cold Spring Harbor perspectives in medicine.

[28]  C. Latkin,et al.  Differences in the social networks of African American men who have sex with men only and those who have sex with men and women. , 2011, American journal of public health.

[29]  H. Masur,et al.  Fighting HIV/AIDS in Washington, D.C. , 2009, Health affairs.

[30]  M. Pérez‐Losada,et al.  Phylodynamics of HIV-1 from a Phase-III AIDS Vaccine Trial in North America , 2009, Molecular biology and evolution.

[31]  A. Greenberg,et al.  Risk factors driving the emergence of a generalized heterosexual HIV epidemic in Washington, District of Columbia networks at risk , 2009, AIDS.

[32]  M. Suchard,et al.  Smooth skyride through a rough skyline: Bayesian coalescent-based inference of population dynamics. , 2008, Molecular biology and evolution.

[33]  D. Posada jModelTest: phylogenetic model averaging. , 2008, Molecular biology and evolution.

[34]  M. D. Miller,et al.  Resistance development over 144 weeks in treatment‐naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903 * , 2006, HIV medicine.

[35]  Tommy F. Liu,et al.  Web resources for HIV type 1 genotypic-resistance test interpretation. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  Christopher D Pilcher,et al.  Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. , 2004, The New England journal of medicine.

[37]  K. Katoh,et al.  MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. , 2002, Nucleic acids research.

[38]  D. Posada,et al.  Selecting models of nucleotide substitution: an application to human immunodeficiency virus 1 (HIV-1). , 2001, Molecular biology and evolution.

[39]  L. Bacheler,et al.  Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy , 2000, Antimicrobial Agents and Chemotherapy.

[40]  K. Crandall,et al.  Effective population sizes: missing measures and missing concepts , 1999 .

[41]  B. Berkhout,et al.  Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins. , 1996, Antiviral research.

[42]  J. Felsenstein CONFIDENCE LIMITS ON PHYLOGENIES: AN APPROACH USING THE BOOTSTRAP , 1985, Evolution; international journal of organic evolution.

[43]  Sudhir Kumar,et al.  MBE Citation Classics (2018 Edition). , 2018, Molecular biology and evolution.

[44]  S. Frost,et al.  Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals , 2016 .

[45]  R. Malinverni [HIV epidemic]. , 1998, Therapeutische Umschau. Revue therapeutique.